NYSE:FMS - Fresenius Medical Care AG & Co. Stock Price, Forecast & News

Fresenius Medical Care AG & Co. trades on the New York Stock Exchange (NYSE) under the ticker symbol "FMS."

Fresenius Medical Care AG & Co. announced an annual dividend on Thursday, May 9th. Shareholders of record on Monday, May 20th will be paid a dividend of $0.6551 per share on Friday, May 31st. This represents a yield of 1.59%. The ex-dividend date is Friday, May 17th. This is a positive change from Fresenius Medical Care AG & Co.'s previous annual dividend of $0.44. View Fresenius Medical Care AG & Co.'s Dividend History.

Fresenius Medical Care AG & Co. (NYSE:FMS) posted its quarterly earnings results on Tuesday, October, 29th. The company reported $0.67 EPS for the quarter, beating the consensus estimate of $0.59 by $0.08. The company had revenue of $4.91 billion for the quarter, compared to analysts' expectations of $4.72 billion. Fresenius Medical Care AG & Co. had a return on equity of 9.92% and a net margin of 7.47%. View Fresenius Medical Care AG & Co.'s Earnings History.

Fresenius Medical Care AG & Co. is scheduled to release their next quarterly earnings announcement on Wednesday, February 19th 2020. View Earnings Estimates for Fresenius Medical Care AG & Co..

10 equities research analysts have issued 1-year target prices for Fresenius Medical Care AG & Co.'s stock. Their forecasts range from $40.23 to $54.00. On average, they expect Fresenius Medical Care AG & Co.'s share price to reach $46.68 in the next year. This suggests a possible upside of 18.3% from the stock's current price. View Analyst Price Targets for Fresenius Medical Care AG & Co..

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fresenius Medical Care AG & Co. in the last year. There are currently 1 sell rating, 5 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Fresenius Medical Care AG & Co..

News articles about FMS stock have trended extremely negative on Sunday, InfoTrie reports. The research firm identifies negative and positive media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Fresenius Medical Care AG & Co. earned a media sentiment score of -4.5 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the near future. View News Stories for Fresenius Medical Care AG & Co..

Fresenius Medical Care AG & Co. saw a increase in short interest in December. As of December 13th, there was short interest totalling 397,100 shares, an increase of 20.6% from the November 28th total of 329,200 shares. Based on an average trading volume of 202,400 shares, the days-to-cover ratio is presently 2.0 days. Approximately 0.1% of the company's shares are short sold. View Fresenius Medical Care AG & Co.'s Current Options Chain.

Some companies that are related to Fresenius Medical Care AG & Co. include Davita (DVA), Progyny (PGNY), Tivity Health (TVTY), HemaCare (HEMA), American Renal Associates (ARA), Catasys (CATS), Emmaus Life Sciences (EMMA), Baudax Bio (BXRX), Caladrius Biosciences (CLBS), Pacific Health Care Organization (PFHO), BioRestorative Therapies (BRTX) and American Caresource (GNOW).

Based on aggregate information from My MarketBeat watchlists, some companies that other Fresenius Medical Care AG & Co. investors own include Petra Diamonds (PDL), Energy Transfer LP Unit (ET), AT&T (T), Ford Motor (F), Teva Pharmaceutical Industries (TEVA), Abbott Laboratories (ABT), CBL & Associates Properties (CBL), Centurylink (CTL), Davita (DVA) and Cigna (CI).

Fresenius Medical Care AG & Co.'s stock is owned by many different of retail and institutional investors. Top institutional shareholders include Campbell & CO Investment Adviser LLC (0.00%), Cascade Investment Advisors Inc. (0.00%), Landsberg Bennett & Dubbaneh LLC (0.00%) and Eqis Capital Management Inc. (0.00%).

FMS stock was sold by a variety of institutional investors in the last quarter, including Eqis Capital Management Inc..

FMS stock was purchased by a variety of institutional investors in the last quarter, including Campbell & CO Investment Adviser LLC, Cascade Investment Advisors Inc. and Landsberg Bennett & Dubbaneh LLC.

Shares of FMS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of FMS stock can currently be purchased for approximately $39.47.

Fresenius Medical Care AG & Co. has a market capitalization of $23.91 billion and generates $19.44 billion in revenue each year. The company earns $2.34 billion in net income (profit) each year or $2.27 on an earnings per share basis. Fresenius Medical Care AG & Co. employs 112,658 workers across the globe.View Additional Information About Fresenius Medical Care AG & Co..

The official website for Fresenius Medical Care AG & Co. is http://www.freseniusmedicalcare.com/.

Fresenius Medical Care AG & Co.'s mailing address is ELSE-KROENER STRASSE 1, BAD HOMBURG 2M, 61352. The company can be reached via phone at 49-6172-608-2522 or via email at [email protected]